Focus: Humanwell Pharmaceutical is a public specialty pharma company headquartered in Missouri focused on anesthetic and pain medications with a diversified portfolio across neurology, cardiovascular, endocrinology, oncology, and nephrology. The company generates significant revenue from branded and generic pain medications.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Humanwell Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Humanwell Pharmaceutical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Humanwell Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship revenue driver at 30% of company total; loses patent protection July 2026 creating immediate commercial cliff.
Extended-release franchise at peak revenue; second largest revenue contributor with longer exclusivity runway through March 2029.
Consolidated multi-indication generic with mature market; represents stable but non-growth revenue stream.
Established antiarrhythmic generic with stable niche cardiology market; no growth catalysts.
30 discontinued, 51 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
+28 more products